Brokerages predict that Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) will report earnings per share of ($0.71) for the current fiscal quarter, Zacks reports. Three analysts have issued estimates for Bellicum Pharmaceuticals’ earnings. The highest EPS estimate is ($0.62) and the lowest is ($0.79). Bellicum Pharmaceuticals reported earnings per share of ($0.80) in the same quarter last year, which would suggest a positive year-over-year growth rate of 11.3%. The firm is expected to announce its next quarterly earnings results on Monday, May 14th.
According to Zacks, analysts expect that Bellicum Pharmaceuticals will report full-year earnings of ($2.68) per share for the current financial year, with EPS estimates ranging from ($3.33) to ($2.22). For the next year, analysts forecast that the business will report earnings of ($2.63) per share, with EPS estimates ranging from ($3.33) to ($2.11). Zacks Investment Research’s earnings per share averages are an average based on a survey of research analysts that that provide coverage for Bellicum Pharmaceuticals.
Bellicum Pharmaceuticals (NASDAQ:BLCM) last issued its quarterly earnings data on Tuesday, March 13th. The biopharmaceutical company reported ($0.61) EPS for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.08. The business had revenue of ($0.07) million during the quarter, compared to analysts’ expectations of $0.08 million.
BLCM has been the subject of a number of recent research reports. ValuEngine raised shares of Bellicum Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Wednesday, January 3rd. BidaskClub raised shares of Bellicum Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Thursday, January 4th. Zacks Investment Research raised shares of Bellicum Pharmaceuticals from a “hold” rating to a “buy” rating and set a $10.00 price target for the company in a research note on Wednesday, January 10th. Wells Fargo cut shares of Bellicum Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $6.00 price target for the company. in a research note on Wednesday, January 31st. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $10.00 price target (down from $12.00) on shares of Bellicum Pharmaceuticals in a research note on Wednesday, January 31st. One analyst has rated the stock with a sell rating, two have given a hold rating and seven have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $17.98.
In related news, major shareholder Bros. Advisors Lp Baker sold 880,735 shares of Bellicum Pharmaceuticals stock in a transaction dated Friday, January 19th. The shares were sold at an average price of $8.20, for a total transaction of $7,222,027.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 18.77% of the stock is currently owned by insiders.
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. MYDA Advisors LLC bought a new stake in Bellicum Pharmaceuticals during the 4th quarter valued at about $118,000. Cubist Systematic Strategies LLC bought a new stake in Bellicum Pharmaceuticals during the 3rd quarter valued at about $164,000. LPL Financial LLC bought a new stake in Bellicum Pharmaceuticals during the 4th quarter valued at about $140,000. Goldman Sachs Group Inc. lifted its holdings in Bellicum Pharmaceuticals by 14.9% during the 4th quarter. Goldman Sachs Group Inc. now owns 148,860 shares of the biopharmaceutical company’s stock valued at $1,252,000 after buying an additional 19,257 shares in the last quarter. Finally, Deutsche Bank AG lifted its holdings in Bellicum Pharmaceuticals by 28.3% during the 4th quarter. Deutsche Bank AG now owns 110,028 shares of the biopharmaceutical company’s stock valued at $924,000 after buying an additional 24,246 shares in the last quarter. Institutional investors own 54.58% of the company’s stock.
Shares of NASDAQ:BLCM opened at $8.26 on Thursday. Bellicum Pharmaceuticals has a 52 week low of $5.02 and a 52 week high of $14.49. The firm has a market capitalization of $301.48, a price-to-earnings ratio of -3.16 and a beta of 0.47. The company has a debt-to-equity ratio of 0.41, a current ratio of 8.37 and a quick ratio of 8.37.
ILLEGAL ACTIVITY NOTICE: “Zacks: Analysts Expect Bellicum Pharmaceuticals, Inc. (BLCM) to Announce -$0.71 Earnings Per Share” was first published by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this news story on another website, it was stolen and reposted in violation of US and international copyright & trademark laws. The correct version of this news story can be accessed at https://transcriptdaily.com/2018/04/17/zacks-analysts-expect-bellicum-pharmaceuticals-inc-blcm-to-announce-0-71-earnings-per-share.html.
Bellicum Pharmaceuticals Company Profile
Bellicum Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. The company's clinical product candidates include BPX-501, an adjunct T cell therapy in multiple Phase I/II clinical trials, administered after allogeneic hematopoietic stem cell transplantation; and BPX-601, a GoCAR-T product candidate in Phase I clinical trial for treating solid tumors expressing the prostate stem cell antigen.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.